aXichem AB Class A (SE:AXIC.A)
:AXIC.A
Want to see SE:AXIC.A full AI Analyst Report?
Top Page
aXichem AB Class A
(AXIC.A)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr1.50
▼(-30.23% Downside)
Action:Reiterated
Date:06/02/26
The score is primarily held back by weak financial performance—ongoing losses, negative gross profit/operating margins, and persistent cash burn—despite strong recent revenue growth and low balance-sheet leverage. Technicals add pressure with the stock trading below major moving averages, while valuation remains constrained by negative earnings and no dividend yield data.
Positive Factors
Accelerating Revenue Growth
A ~55% YoY revenue acceleration in 2025 shows the business is gaining commercial traction and expanding end-market adoption. Sustained top-line growth over multiple quarters can support scale-related margin improvement, greater bargaining power with customers, and a clearer path to eventual profitability.
Negative Factors
Persistent Negative Cash Flow
Consistent negative operating and free cash flow indicate the business is not self-funding and relies on external capital. Over months this raises dilution and refinancing risk, limits reinvestment capacity, and creates execution risk if capital markets become less accessible or financing terms worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
A ~55% YoY revenue acceleration in 2025 shows the business is gaining commercial traction and expanding end-market adoption. Sustained top-line growth over multiple quarters can support scale-related margin improvement, greater bargaining power with customers, and a clearer path to eventual profitability.
Read all positive factors
aXichem AB Class A (AXIC.A) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr87.71M
Dividend YieldN/A
Average Volume (3M)26.22K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth69.39%
EPS Growth35.69%
CountrySE
Employees7
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.41
Shares Outstanding67,729,120
10 Day Avg. Volume21,219
30 Day Avg. Volume26,221
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)kr38.19M
aXichem AB Class A Business Overview & Revenue Model
Company Description
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health appl...
How the Company Makes Money
aXichem makes money primarily by selling products and/or active ingredients based on its proprietary compound phenylcapsaicin, with the most publicly emphasized commercial path being feed-related applications (i.e., supplying phenylcapsaicin as an...
aXichem AB Class A Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.93M | 18.45M | 8.57M | 1.81M | 5.01M | 4.36M |
| Gross Profit | 7.06M | -14.51M | 7.08M | 1.41M | 3.82M | 909.00K |
| EBITDA | -15.10M | -12.04M | -11.55M | -15.10M | -12.44M | -13.49M |
| Net Income | -20.51M | -17.63M | -17.81M | -20.81M | -17.26M | -15.09M |
Balance Sheet | ||||||
| Total Assets | 68.18M | 61.09M | 74.28M | 61.49M | 61.25M | 58.77M |
| Cash, Cash Equivalents and Short-Term Investments | 6.78M | 3.08M | 14.36M | 4.31M | 6.55M | 9.45M |
| Total Debt | 3.09M | 4.73M | 0.00 | 10.27M | 18.76M | 0.00 |
| Total Liabilities | 7.13M | 8.22M | 4.13M | 12.96M | 20.92M | 2.47M |
| Stockholders Equity | 61.02M | 52.86M | 70.13M | 48.51M | 40.31M | 56.30M |
Cash Flow | ||||||
| Free Cash Flow | -10.94M | -16.00M | -11.50M | -15.68M | -21.71M | -20.32M |
| Operating Cash Flow | -10.94M | -11.35M | -11.50M | -15.68M | -19.10M | -15.60M |
| Investing Cash Flow | -6.63M | -4.66M | -6.50M | -5.10M | -2.61M | -4.73M |
| Financing Cash Flow | 14.32M | 4.73M | 28.05M | 18.54M | 18.80M | 17.73M |
aXichem AB Class A Technical Analysis
Negative
2.15
Price Trends
1.38
Negative
1.40
Negative
2.03
Negative
Market Momentum
-0.03
Positive
43.09
Neutral
39.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:AXIC.A, the sentiment is Negative. The current price of 2.15 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.38, and above the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.09 is Neutral, neither overbought nor oversold. The STOCH value of 39.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:AXIC.A.
aXichem AB Class A Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
55 Neutral | kr311.58M | -14.27 | -9.48% | ― | -4.50% | -62.45% | |
47 Neutral | kr53.38M | -4.00 | ― | ― | ― | ― | |
44 Neutral | kr87.71M | -5.40 | -29.85% | ― | 69.39% | 35.69% | |
44 Neutral | kr49.11M | -0.80 | -75.93% | 0.00% | 28.17% | 58.48% | |
42 Neutral | kr86.53M | -1.25 | -153.91% | ― | -21.13% | -66.28% |
* Basic Materials Sector Average
SE:AXIC.A
aXichem AB Class A
1.32
-1.46
-52.68%
SE:NEXAM
Nexam Chemical Holding AB
3.21
-0.66
-17.05%
SE:AERO
Svenska Aerogel Holding AB
0.99
-0.39
-28.55%
SE:ORGC
OrganoClick AB
0.41
-1.47
-78.15%
SE:XPC
XP Chemistries AB
0.18
-0.06
-26.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.